This Site Is Intended For US Healthcare Professionals Only
This Site Is Intended For US Healthcare Professionals Only
Available doses: 10mg/5mg, 10mg/10mg, 10mg/20mg, 10mg/40mg
Patients pay a single generic co-pay for the generic
Co-pay between $5 to $25 p.m. based on patient's insurance
No Prior Auth required (please ignore if PA shows in EMR/EHR)
Use GoodRx: Patients typically pay $15 to $30 p.m.
On rosuvastatin-ezetimibe 40-10 mg, most CHD patients achieved their LDL-C goal† of < 70 mg/dL
Only 35% of CHD patients on the highest dose of rosuvastatin achieved LDL-C goal† of < 70 mg/dL
† In the Explorer Study, 469 patients aged ≥ 18 years with hypercholesterolemia and a history of CV risk were randomized on rosuvastatin + ezetimibe 40 mg/10 mg vs. rosuvastatin 40 mg for a total of 6-weeks. Primary endpoint was % of patients at LDL-C goal < 100 mg/dL. Secondary endpoint for CHD patients was % at LDL-C goal < 70 mg/dL.
ezetimibe-rosuvastatin is a generic version of Roszet (rosuvastatin-ezetimibe) tablets
Roszet adverse experiences1 are expected to be similar to those with co-administered rosuvastatin
and ezetimibe taken separately.
Rosuvastatin (AEs ≥2% of patients) | ||
---|---|---|
Adverse Reaction | Placebo N=382 | Total Rosuvastatin 5 mg-40 mg N=744 |
Headache | 5.0% | 5.5% |
Nausea | 3.1% | 3.4% |
Myalgia | 1.3% | 2.8% |
Asthenia | 2.6% | 2.7% |
Constipation | 2.4% | 2.4% |
Ezetimibe with S tatins (AEs ≥2% of patients) | ||
---|---|---|
Adverse Reaction | All Statins (%), n=9361 | Ezetimibe + statins (%) N=11,308 |
Nasopharyngitis | 3.3% | 3.7% |
Myalgia | 2.7% | 3.2% |
Upper respiratory tract infection | 2.8% | 2.9% |
Arthralgia | 2.4% | 2.6% |
Diarrhea | 2.2% | 2.5% |
Back pain | 2.3% | 2.4% |
Influenza | 2.1% | 2.2% |
Pain in extremity | 1.9% | 2.1% |
Fatigue | 1.6% | 2.0% |
GoodRx is a trademark of GoodRx, Inc.
Important Safety Information